Skip to content

Public FDA record

Z-2603-2011: Encompass Hip Stem, Plasma Spray, 12/14 Taper, Extended, REF 109-XXXX, Sterile R, Ortho Development, Drap

Recall record Z-2603-2011 for Ortho Development Corporation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2603-2011
Company in FDA record
Ortho Development Corporation
FDA classification date
Jun 20, 2011
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 17, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Tests on PVC packaging material resulted in alert levels for cytotoxicity.

Source facts

Action
Ortho Development Corporation notified consignees by letter on May 11, 2011. The letter identified the product, the problem, and the action to be taken by the consignee. Consignees were instructed to return all remaining affected units to Ortho. Replacement product was to be shipped by May 31.
Initiated
2011-05-10
Root cause
Package design/selection
Terminated
2011-11-09
Distribution
Nationwide Distribution - USA including CA, FL, and TX.
Recall number
Z-2603-2011
Recall status
Terminated
CDRH record ID
100317
FDA classified
2011-06-20
Recall event number
58763

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗